Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866816 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10762236 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10758278 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL25304331 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10761324 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL25304326 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10762232 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL5707859 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL17866867 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL10762227 | 1.00 | LMNA (0.42) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590282-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO | NovoArc GmbH (AT) | 2025-07-30 | — | — | EP | claimed |
| US-20250084116-A1 | MIXTURE OF STEREOISOMERS OF A SULFATED GLYCOLIPID | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2025-03-13 | — | — | US | claimed |
| EP-4460328-A1 | MIXTURE OF STEREOISOMERS OF A SULFATED GLYCOLIPID | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-11-13 | — | — | EP | claimed |
| US-20240366747-A1 | UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-11-07 | — | — | US | claimed |
| EP-4421174-A2 | ADJUVANT COMPRISING A GLYCOARCHAEOL AND AN IMMUNOSTIMULANT | National Research Council of Canada (CA) | 2024-08-28 | — | — | EP | claimed |
| EP-4370152-A1 | UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024062001-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO | NOVOARC GMBH (AT) | 2024-03-28 | — | — | WO | claimed |
| EP-4342460-A1 | LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO | NovoArc GmbH (AT) | 2024-03-27 | — | — | EP | claimed |
| US-20240082391-A1 | ADJUVANT COMPRISING A GLYCOARCHAEOL AND AN IMMUNOSTIMULANT | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-03-14 | — | — | US | claimed |
| EP-4274610-A1 | ADJUVANT COMPRISING A GLYCOARCHAEOL AND AN IMMUNOSTIMULANT | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-11-15 | — | — | EP | claimed |
| US-8936793-B2 | Synthetic archaeal glycolipid adjuvants | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2015-01-20 | — | — | US | claimed |
| WO-2014143806-A1 | ACID STABLE LIPOSOMAL COMPOSITIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | WO | claimed |
| US-20140271824-A1 | Acid Stable Liposomal Compositions And Methods For Producing The Same | THE PENN STATE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | claimed |
| WO-2013105026-A1 | A PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2013-07-18 | — | — | WO | claimed |
| CN-1988970-B | Method for stimulating the production of methane from petroleum in subterranean formations | UNIV NEWCASTLE | 2012-05-16 | — | — | CN | claimed |
| US-20100316657-A1 | Synthetic Archaeal Glycolipid Adjuvants | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-12-16 | — | — | US | claimed |
| EP-1999137-A1 | SYNTHETIC ARCHAEAL GLYCOLIPID ADJUVANTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-12-10 | — | — | EP | claimed |
| WO-2007112567-A1 | SYNTHETIC ARCHAEAL GLYCOLIPID ADJUVANTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2007-10-11 | — | — | WO | claimed |
| CN-1988970-A | Method for stimulating the production of methane from petroleum in subterranean formations | UNIV NEWCASTLE (GB) | 2007-06-27 | — | — | CN | claimed |
| US-20040214259-A1 | Methods of sampling microbial communities and apparatus therefore | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082391-A1 | ADJUVANT COMPRISING A GLYCOARCHAEOL AND AN IMMUNOSTIMULANT | TLR7, TLR9, TLR1 | LMNA 4364/4885BLM 2082/4885PTPN1 450/4885 |
| US-20250084116-A1 | MIXTURE OF STEREOISOMERS OF A SULFATED GLYCOLIPID | DEGS1, SGMS1, SGMS2 | LMNA 4698/4885BLM 3778/4885PTPN1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.